Post-acute COVID syndrome(PACS) diagnosis.
Conditions
Brief summary
Short Physical Performance Battery, Frailty reversibility, Quality of life assessed with EQ 5D-5L
Detailed description
Identification of the main changes in peripheral blood cells that identify the immune risk phenotype (CD4/CD8 T cell ratio, senescent/activated CD8+ T cells, number of B lymphocytes and NK cells), Evaluation of the change that occur in the plasma level of the main inflammatory and anti-inflammatory cytokines, chemokines and their receptors., Analysis of the differences in monocyte activation and phenotypes (inflammatory, classical, non classical) among groups, The occurrence of adverse events (AEs), changes on clinical examination including vital signs and weight, and laboratory examinations (biochemistry, hematology and urinalysis)
Interventions
DRUGMETFORMIN
DRUGSIROLIMUS
Sponsors
Azienda Ospedaliero Universitaria Di Modena
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Short Physical Performance Battery, Frailty reversibility, Quality of life assessed with EQ 5D-5L | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of the main changes in peripheral blood cells that identify the immune risk phenotype (CD4/CD8 T cell ratio, senescent/activated CD8+ T cells, number of B lymphocytes and NK cells), Evaluation of the change that occur in the plasma level of the main inflammatory and anti-inflammatory cytokines, chemokines and their receptors., Analysis of the differences in monocyte activation and phenotypes (inflammatory, classical, non classical) among groups, The occurrence of adverse events (AEs), changes on clinical examination including vital signs and weight, and laboratory examinations (biochemistry, hematology and urinalysis) | — |
Countries
Italy
Outcome results
None listed